Biology subjects

Jeong, C.-U.

Publications and source records attributed to Jeong, C.-U..

3 recordsLinked to original sources

bioRxiv2026

Limits of marker information transfer]{Limits of marker information transfer in cross-panel cytometry imputation

Marker imputation can bridge cytometry datasets acquired with different panels and platforms. Its validity depends on whether common markers retain information about unmeasured target markers and whether those relationships transfer across assay contexts. We evaluated these limits in two paired flow cytometry-CyTOF cohorts comprising 134 patients and 257 specimens. A patient-held-out framework distinguished within-platform same-cell reconstruction from cross-platform distribution translation without cell correspondence. We compared conventional machine-learning and deep generative estimators with median imputation and used permutation controls to estimate the contributions of patient matching and source-exclusive markers. Evaluation covered marker values, specimen distributions, phenotype utility, and directional predictive relationships among markers. Within platforms, exact k-nearest neighbors reduced mean absolute error by 12.8-35.0% relative to median imputation. However, the median-based reconstructions were contracted, with a median ratio of predicted to observed interquartile range below 1 in every context and evaluable population. Patient matching improved cross-platform distribution recovery, whereas adding source-exclusive markers or higher-capacity estimators did not consistently produce net gains. In the independently annotated acute myeloid leukemia (AML) cohort, reconstructed markers largely preserved broad-lineage classification but did not recover fine-phenotype information available through direct measurement. In AML-CyTOF, the measured full panel outperformed the reconstructed representation by 10.25 percentage points for fine phenotypes. Predictive relationships among markers were context-specific. Most targets were better explained by several markers than by one. Marker selection based on these relationships showed a trade-off between panel size and pairwise coverage. Paired samples and imputation can therefore connect selected marker distributions across panels but should not be treated as substitutes for direct measurement. Cross-panel cytometry should be evaluated with patient-held-out tests matched to the resolution of available ground truth and the intended downstream use.

bioinformatics↗

bioRxiv2026

CytoGate-Bench: an LLM benchmark for cross-panel cell gating in cytometry

In cytometry, the workhorse single-cell technology of clinical immunology, every study defines its own antibody panel and cell-type vocabulary, so a classifier trained on one cannot annotate the next. Immunologists instead annotate by manual gating, splitting one parent population at a time on a two-marker plot, down an expert-defined hierarchy. We introduce CytoGate-Bench, a benchmark that reformulates this per-step procedure as a zero-shot, panel-agnostic task for large language models. It comprises 23,646 expert-annotated instances re-curated from 11 public flow- and mass-cytometry cohorts spanning eight marker panels. Across six open- and closed-weight backbones, the strongest formulation draws one rectangular gate per candidate and falls within the range of trained, panel-specialized baselines. It degrades less under distribution shift. Walking the hierarchy stepwise outperforms predicting every cell type at once. Ablations trace the signal to the data distribution shape and curated marker priors. However, adding vision or a self-verification loop systematically tightens gates.

bioinformatics↗

bioRxiv2026

Deep learning representations of human Immune Health for precision immunology

The human immune system is composed of [~]30-50 distinct cell types, each of which can exist in different states of activation or differentiation. Indeed, the mammalian immune system has evolved to sense and respond to infections, cancers, injuries, and changes in tissue or host homeostasis (1). Moreover, an increasingly large fraction of approved drugs target the immune system directly, and/or cause immune changes (2-4). A key feature of the immune system is to store some of this information, for example as innate or adaptive immune memory (5). In addition, rewiring of immune network architecture induced by disease, environmental exposures, drug treatments, and/or chronological age allows the immune system to store information in the pattern of connections and activity across populations of immune cells. This ensemble information storage, in addition to changes to individual cells, functions as a major way the immune system encodes aspects of immune history and future potential. Genetic information can identify inherited risk alleles, but cannot capture the continual remodeling of the immune system shaped by exposures, infection, inflammation, therapy, and aging (6, 7). To define and use such ensemble immunotypes, we developed a self-supervised deep learning framework that transforms high-dimensional immune profiles into representations of immune health. MAESTRO (MAsked Encoding Set TRansformer with self-distillatiOn) encodes a set of cells from an individual into an embedding that captures immune cell population-level organization. Pretrained on 1,792 peripheral blood samples comprising over 418 million immune cells across 13 clinical diagnoses, MAESTRO learns immune fingerprints that are stable within individuals yet diverse across populations, states of health, disease, and treatment, providing a quantitative basis for comparing immune states across individuals and over time. These fingerprints capture immune architecture beyond coarse cell type proportions, enabling patient-efficient clinical prediction using simple task specific models. MAESTRO model embeddings retain a temporal dimension of immune history and potential, reflecting signatures of past exposures and baseline features that predict future immune responses. Finally, we demonstrate a translational precision immunotherapy application by testing this approach in metastatic Pancreatic Ductal Adenocarcinoma (PDAC), where pretreatment immune landscape circuitry maps enable patient stratification and therapeutic response prediction. Overall, we developed a large, attention-based model that captures deep network architecture of immune states through self- supervised representations of immune cytometry data as a reusable foundation for precision immunology, converting immune complexity into clinically actionable embeddings for diagnosis, monitoring, and therapy selection.

immunology↗